Understanding how Disabled-2 affects breast cancer pathways
Disabled-2 in the metabolic regulation of oncopathways
['FUNDING_R03'] · BAYLOR COLLEGE OF MEDICINE · NIH-10757684
This study is looking at how a protein called Disabled-2 affects important signals in triple-negative breast cancer, which is a tough type of breast cancer to treat, with the goal of finding new ways to help improve treatment for patients.
Quick facts
| Phase | ['FUNDING_R03'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BAYLOR COLLEGE OF MEDICINE (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10757684 on ClinicalTrials.gov |
What this research studies
This research investigates the role of Disabled-2 in regulating key signaling pathways involved in triple-negative breast cancer (TNBC), a type of breast cancer known for its aggressive nature and limited treatment options. The study focuses on mitochondrial retrograde signaling and how it influences the phosphorylation of the Src oncogene, which is crucial for tumor growth and metastasis in TNBC. By exploring the mechanisms behind this regulation, the research aims to uncover new therapeutic targets that could improve treatment outcomes for patients with TNBC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who may benefit from novel therapeutic approaches.
Not a fit: Patients with hormone receptor-positive breast cancer or other non-TNBC subtypes may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that specifically target the aggressive pathways in triple-negative breast cancer, potentially improving survival rates.
How similar studies have performed: While the specific role of Disabled-2 in TNBC is being explored for the first time, similar approaches targeting oncogenic pathways have shown promise in other cancer types.
Where this research is happening
HOUSTON, UNITED STATES
- BAYLOR COLLEGE OF MEDICINE — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KAIPPARETTU, BENNY ABRAHAM — BAYLOR COLLEGE OF MEDICINE
- Study coordinator: KAIPPARETTU, BENNY ABRAHAM
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Cancers, neoplasm/cancer